MarketCap
Facebook
X
Telegram
Country |
 USA |
IPO year |
2010 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ CAPITAL |
Shares |
34.4 M |
Market Cap[1] |
$ 521 M |
EBITDA (LTM) |
- |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Gossamer Bio
GOSS
|
$ 11.2 | 5.21 % | $ 2.56 B | Nasdaq Global Select Market,SPB | USA |
 |
GeoVax Labs
GOVX
|
$ 0.11 | -22.17 % | $ 105 K | Nasdaq Global Select Market | USA |
 |
United Therapeutics Corporation
UTHR
|
$ 588.33 | 1.01 % | $ 26.1 B | Nasdaq Global Select Market,SPB | USA |
 |
Seelos Therapeutics
SEEL
|
- | -47.76 % | $ 6.27 M | Nasdaq Capital Market | USA |
 |
Vericel Corporation
VCEL
|
$ 59.02 | 1.08 % | $ 2.97 B | Nasdaq Global Select Market,SPB | USA |
 |
Veracyte
VCYT
|
$ 24.05 | -7.21 % | $ 1.89 B | Nasdaq Global Market,SPB | USA |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
GlaxoSmithKline plc
GSK
|
$ 51.25 | -0.56 % | $ 208 B | NYSE |  Britain |
 |
Vir Biotechnology
VIR
|
$ 13.17 | -3.48 % | $ 1.82 B | Nasdaq Global Select Market,SPB | USA |
 |
Viking Therapeutics
VKTX
|
$ 28.67 | -1.1 % | $ 3.23 B | Nasdaq Capital Market | USA |
 |
Vanda Pharmaceuticals
VNDA
|
$ 4.07 | -0.49 % | $ 240 M | Nasdaq Global Select Market,SPB | USA |
 |
Verrica Pharmaceuticals
VRCA
|
$ 3.55 | -1.11 % | $ 37.8 M | Nasdaq Global Market | USA |
 |
Vertex Pharmaceuticals Incorporated
VRTX
|
$ 547.74 | -0.57 % | $ 140 B | Nasdaq Global Select Market,SPB | USA |
 |
Kiromic BioPharma
KRBP
|
- | 6.61 % | $ 3.08 M | Nasdaq Global Select Market | USA |
 |
vTv Therapeutics
VTVT
|
$ 20.88 | -1.42 % | $ 83.8 M | Nasdaq Global Select Market | USA |
 |
CNS Pharmaceuticals
CNSP
|
$ 3.81 | -3.3 % | $ 1.69 M | Nasdaq Capital Market | USA |
 |
Voyager Therapeutics
VYGR
|
$ 1.82 | -8.54 % | $ 107 M | Nasdaq Global Select Market | USA |
 |
Calithera Biosciences
CALA
|
- | -10.95 % | $ 876 K | Nasdaq Global Select Market | USA |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Wave Life Sciences Ltd.
WVE
|
$ 3.41 | -2.01 % | $ 575 M | Nasdaq Global Select Market |  Singapore |
 |
Molecular Templates
MTEM
|
- | -23.43 % | $ 495 K | Nasdaq Capital Market | USA |
 |
Exicure
XCUR
|
$ 1.08 | 21.31 % | $ 6.8 M | Nasdaq Capital Market | USA |
 |
Immunome
IMNM
|
$ 18.65 | -3.67 % | $ 1.63 B | Nasdaq Global Select Market | USA |
 |
Xeris Pharmaceuticals
XERS
|
$ 15.81 | -0.35 % | $ 2.54 B | Nasdaq Global Select Market | USA |
 |
X4 Pharmaceuticals
XFOR
|
$ 3.24 | -2.7 % | $ 137 M | Nasdaq Capital Market | USA |
 |
Xencor
XNCR
|
$ 39.42 | 2.16 % | $ 2.93 B | Nasdaq Global Select Market,SPB | USA |
 |
INmune Bio
INMB
|
$ 1.09 | -3.54 % | $ 27 M | Nasdaq Capital Market | USA |
 |
Insmed Incorporated
INSM
|
$ 119.55 | 2.97 % | $ 23.8 B | Nasdaq Global Select Market | USA |
 |
Ionis Pharmaceuticals
IONS
|
$ 28.02 | -9.63 % | $ 4.48 B | Nasdaq Global Select Market,SPB | USA |
 |
BioXcel Therapeutics
BTAI
|
$ 0.07 | 9.81 % | $ 855 K | Nasdaq Global Select Market,SPB | USA |
 |
InflaRx N.V.
IFRX
|
$ 1.21 | -7.63 % | $ 81.4 M | Nasdaq Global Select Market |  Germany |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
$ 1.78 | 16.33 % | $ 1.2 B | Nasdaq Capital Market |  Israel |
 |
22nd Century Group
XXII
|
$ 1.46 | -10.43 % | $ 269 K | NYSE American | USA |
 |
Ironwood Pharmaceuticals
IRWD
|
$ 4.82 | 2.99 % | $ 780 M | Nasdaq Global Select Market | USA |
 |
Jazz Pharmaceuticals plc
JAZZ
|
$ 245.39 | 0.76 % | $ 15 B | Nasdaq Global Select Market |  Irlanda |
 |
Zai Lab Limited
ZLAB
|
$ 26.56 | -1.12 % | $ 29.1 B | Nasdaq Global Select Market |  China |
 |
Zentalis Pharmaceuticals
ZNTL
|
$ 1.8 | 3.16 % | $ 129 M | Nasdaq Global Market | USA |
 |
CohBar
CWBR
|
- | -15.44 % | $ 2.2 M | Nasdaq Capital Market | USA |
 |
Zoetis
ZTS
|
$ 82.45 | 0.15 % | $ 36.6 B | NYSE,SPB | USA |
 |
NeuBase Therapeutics
NBSE
|
- | -1.56 % | $ 12.3 M | Nasdaq Global Select Market | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
- | - | $ 2.18 B | Nasdaq Global Select Market,SPB | USA |
 |
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | USA |
 |
Scopus BioPharma
SCPS
|
- | -48.37 % | $ 3.71 M | Nasdaq Global Select Market | USA |
 |
Annovis Bio
ANVS
|
$ 0.85 | -5.53 % | $ 17.5 M | NYSE American | USA |
 |
scPharmaceuticals
SCPH
|
- | - | $ 218 M | Nasdaq Global Select Market | USA |
 |
Johnson & Johnson
JNJ
|
$ 281.13 | -0.35 % | $ 677 B | NYSE,SPB | USA |
 |
Kala Pharmaceuticals
KALA
|
$ 0.17 | -2.59 % | $ 1.39 M | Nasdaq Global Select Market | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
- | - | $ 105 M | Nasdaq Global Market | USA |
 |
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | USA |
 |
Global Blood Therapeutics
GBT
|
- | - | $ 4.62 B | Nasdaq Global Select Market,SPB | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.